Health Care [ 11/12 ] | Biotechnology [ 66/74 ]
NASDAQ | Common Stock
Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2.
Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021.
The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020.
The company was incorporated in 2019 and is based in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.18 Increased by +52.08% | - |
| May 2, 24 | -0.23 Increased by +68.06% | -0.20 Decreased by -15.00% |
| Mar 6, 24 | -0.19 Increased by +76.83% | -0.24 Increased by +20.83% |
| Nov 2, 23 | -0.25 Increased by +85.03% | -0.32 Increased by +21.88% |
| Aug 3, 23 | -0.37 Increased by +56.98% | -0.32 Decreased by -15.62% |
| May 15, 23 | -0.72 Increased by +2.70% | -0.59 Decreased by -22.03% |
| Mar 9, 23 | -0.82 Decreased by -100.00% | -0.78 Decreased by -5.13% |
| Nov 3, 22 | -1.67 Decreased by -215.09% | -1.30 Decreased by -28.46% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 0.00 Decreased by N/A% | -10.71 M Increased by +37.24% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 58.00 K Increased by +N/A% | -7.90 M Increased by +58.52% | Decreased by -13.62 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.64 M Increased by +72.83% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -10.11 M Increased by +48.78% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -17.06 M Increased by +0.72% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -19.04 M Decreased by -97.90% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -39.14 M Decreased by -219.09% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -19.74 M Decreased by -290.18% | Decreased by N/A% Decreased by N/A% |